
The FDA approved the oral SERD giredestrant with everolimus for ESR1-mutated, ER-positive, HER2-negative advanced breast cancer based on phase 3 evERA data.
Deanna J. Attai, MD, assistant clinical professor, Department of Surgery, UCLA, discusses breast cancer survivor support and education on Twitter.
Deanna J. Attai, MD, assistant clinical professor, Department of Surgery, UCLA, discusses breast cancer survivor support and education on Twitter.
<<<






